Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026. Stockholders elected Class III directors Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., with about 25.4 million votes for and 13.2 million votes withheld for each, plus 25,098,629 broker non-votes.
Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 100 million shares to 200 million shares, with 61,004,221 votes for, 2,394,208 against, and 305,605 abstentions. They also ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.
Rein Therapeutics, Inc. is the subject of an Amendment No. 3 to a Schedule 13G filed by a group of Voss-managed investment entities and Travis W. Cocke reporting their beneficial ownership of the company’s common stock.
Voss Value Master Fund beneficially owned 1,000,000 shares (about 1.2% of the class) and Voss Value-Oriented Special Situations Fund owned 500,000 shares (about 0.6%). Through their roles as general partner and investment manager, Voss Advisors GP, LLC and Voss Capital, L.P. may be deemed to beneficially own these shares plus 4,156,957 shares held in Voss Managed Accounts, for aggregate beneficial ownership of 5,656,957 shares, or approximately 6.6% of Rein Therapeutics’ outstanding common stock. Travis W. Cocke, as managing member of Voss Capital and Voss GP, may likewise be deemed to beneficially own 5,656,957 shares, or about 6.6%. Percentages are based on 85,539,032 shares outstanding as of May 13, 2026.
Rein Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on July 20, 2026. Holders of 85,539,032 shares of common stock outstanding as of May 21, 2026 may participate and vote online.
Key items include electing two Class III directors to terms ending in 2029, approving an amendment to double authorized common shares from 100 million to 200 million, ratifying CBIZ CPAs P.C. as auditor for 2026, and an advisory vote on named executive officer compensation. The proxy also outlines the company’s classified board, committee structure, insider trading, anti-hedging and clawback policies, and details executive pay, including a $575,000 base salary and $287,500 bonus for the CEO in 2025.
Rein Therapeutics director Josef H. von Rickenbach reported a series of open-market purchases of Rein Therapeutics, Inc. common stock. Between May 21 and May 27, 2026, he bought a total of 47,060 shares at weighted average prices slightly above $1.00 per share.
The individual purchases were 3,420 shares at $1.0422 on May 21, 15,950 shares at $1.0475 on May 22, 23,190 shares at $1.0552 on May 26, and 4,500 shares at $1.0708 on May 27, all as non-derivative common stock transactions. Following these purchases, he directly owns 62,514 shares of Rein Therapeutics common stock.
Rein Therapeutics, Inc. is soliciting proxies for its 2026 annual meeting to be held virtually on July 20, 2026. Key items include election of two Class III directors and a proposal to amend the restated certificate of incorporation to increase authorized common stock from 100,000,000 to 200,000,000, effective upon filing.
As of the record date, there were 85,539,032 shares of common stock outstanding and 13,395,836 shares reserved for issuance for warrants, options and RSUs; only 1,065,132 authorized shares remained unissued and unreserved as of May 13, 2026. The proxy also seeks ratification of CBIZ CPAs P.C. as auditor and an advisory vote on named executive officer compensation.
Rein Therapeutics, Inc. reported a net loss of $5.8 million for the quarter ended March 31, 2026, similar to the $5.5 million loss a year earlier, as it continues to invest in drug development without product revenue. Research and development expenses were $3.1 million and general and administrative expenses were $2.2 million, reflecting its focus on advancing its lead asset.
The company is developing LTI-03 for idiopathic pulmonary fibrosis and is running the Phase 2 RENEW trial, a global, randomized, placebo-controlled study targeting about 120 patients. It dosed the first patient in March 2026 and expects interim topline data in the fourth quarter of 2026.
Cash and cash equivalents were $4.4 million as of March 31, 2026, but in May 2026 Rein raised gross proceeds of $57.5 million in an underwritten offering of 57.5 million shares at $1.00 per share. Management believes the resulting liquidity should fund operations, including completion of the Phase 2 RENEW trial, into the first quarter of 2028, though the company still has an accumulated deficit of $407.1 million and expects continued operating losses.
Rein Therapeutics, Inc. director and officer James Brian Windsor reported both a stock purchase and a new option grant. On April 30, 2026, he bought 25,000 shares of common stock at $1.00 per share in the company’s follow-on public offering, bringing his direct common stock holdings to 27,046 shares.
On May 8, 2026, he received a stock option covering 150,000 shares of common stock at an exercise price of $1.17 per share, expiring on May 8, 2036. Twenty-five percent of the option is scheduled to vest on May 8, 2027, with the remainder vesting in equal monthly installments through May 8, 2031.
Rein Therapeutics, Inc. Schedule 13G/A reports detailed beneficial‑ownership disclosures by a Bios/Cavu investor group, listing shared voting and dispositive power across multiple Bios funds and related entities. The filing shows aggregate named positions (examples: 7,797,502 shares / 9.99% for several affiliated holders) and explains a 9.99% beneficial‑ownership blocker tied to the Series X Preferred Stock. The cover pages are used to populate Item 4 ownership figures and the filing includes a notice regarding dissolution of the group; further filings will be made by members in their individual capacities if required.
Rein Therapeutics, Inc. ownership disclosure: a Lynwood group reports beneficial ownership of 4,750,000 shares of Common Stock, representing 6.1% of the class as of May 4, 2026. The percentages are based on 78,039,032 shares outstanding as of May 4, 2026.
The Schedule 13G names Lynwood Capital Management Inc., Benjamin Shapiro and Lynwood Opportunities Master Fund as reporting persons and states the Fund directly beneficially owns the reported shares, with the Investment Manager and Mr. Shapiro potentially deemed to beneficially own those shares.